Mitigating preventable chronic disease: Progress report of the Cleveland Clinic's Lifestyle 180 program

Elizabeth Hw Ricanati, Mladen Golubić, Dongsheng Yang, Leif Saager, Edward J Mascha, Michael F Roizen, Elizabeth Hw Ricanati, Mladen Golubić, Dongsheng Yang, Leif Saager, Edward J Mascha, Michael F Roizen

Abstract

Background: Poor lifestyle choices are key in development and progression of preventable chronic diseases. The purpose of the study was to design and test a program to mitigate the physical and fiscal consequences of chronic diseases.

Methods: Here we report the outcomes for 429 participants with one or more chronic conditions, including obesity, hypertension, hyperlipidemia and diabetes mellitus, many of whom had failed traditional disease management programs, who enrolled into a comprehensive lifestyle intervention. The Lifestyle 180 program integrates nutrition, physical activity and stress management interventions and was conducted at the Wellness Institute of the Cleveland Clinic, United States. An intensive 6 week immersion course, with 8 hours of group instruction per week, was followed by 3 follow-up, 4 hour-long sessions over the course of 6 months.

Results: Changes in biometric (weight, height, waist circumference, resting heart rate and blood pressure) and laboratory variables (fasting lipid panel, blood glucose, insulin, hemoglobin A1c, ultra sensitive C-reactive protein) at 6 months were compared with baseline (pre-post analysis). At week 30, biometric and laboratory data were available for 244 (57%) and 299 (70%) participants, respectively. These had a mean ± SD reduction in weight (6.8 ± 6.9 kg, P < 0.001), waist circumference (6.1 ± 7.3 cm, P < 0.001), glucose (4.5 ± 29.6 mg/dL or 0.25 ± 1.64 mmol/L, P = 0.009), triglycerides (26.4 ± 58.5 mg/dL or 0.30 ± 0.66 mmol/L, P < 0.001), low-density lipoprotein cholesterol (LDL) (7.9 ± 25.1 mg/dL or 0.2 ± 0.65 mmol/L, P < 0.001), hemoglobin A1c (HgbA1c) (0.20 ± 0.64%, P = 0.001), insulin (3.8 ± 11 microU/ml or 26.6 ± 76.4 ρmol, P < 0.001) and ultra sensitive C-reactive protein (US - CRP) (0.9 ± 4.8 mg/dL or 7.3 ± 40.2 nmol/L, P = 0.012), an increase in mean high-density lipoprotein cholesterol (HDL) (3.7 ± 8.4 mg/dL or 0.1 ± 0.22, P < 0.001), and decreased use of medications.

Conclusion: Implementation of a comprehensive lifestyle modification program among adults with common chronic conditions results in significant and clinically meaningful improvements in biometric and laboratory outcomes after 6 months.

Figures

Figure 1
Figure 1
Boxplots comparing weeks 1, 6 and 30 in each biometric variable using all non-missing data. SBP denotes systolic blood pressure (mmHg). Box shows the interquartile range; horizontal line marks the median; whiskers extend to high and low values within 1.5 interquartile range of the box; circles are values beyond 1.5 interquartile ranges of the box; diamond shows the mean.
Figure 2
Figure 2
Mean change (97.5% CI) in metabolic outcomes at six and thirty weeks from baseline. Abbreviations: HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol.

References

    1. Willett WC. Balancing Life-Style and Genomics Research for Disease Prevention. Science. 2002;296:695–698. doi: 10.1126/science.1071055.
    1. World Health Organization. Diet, Nutrition and the Prevention of Chronic Diseases. WHO Technical Report Series 916. 2003.
    1. Ford ES, Bergmann MM, Kröger J, Schienkiewitz A, Weikert C, Boeing H. Healthy living is the best revenge: findings from the European Prospective Investigation Into Cancer and Nutrition-Potsdam study. Arch Intern Med. 2009;169(15):1355–62. doi: 10.1001/archinternmed.2009.237.
    1. American College of Preventive Medicine: Lifestyle Medicine-Evidence Review. 2009. Accessed July 4, 2010.
    1. Ornish D, Scherwitz LW, Billings JH, Brown SE, Gould KL, Merritt TA. et al.Intensive Lifestyle Changes for Reversal of coronary heart disease. JAMA. 1998;280(23):2001–7. doi: 10.1001/jama.280.23.2001.
    1. Silberman A, Banthia R, Estay IS, Kemp C, Studley J, Hareras D, Ornish D. The effectiveness and efficacy of an intensive cardiac rehabilitation program in 24 sites. Am J Health Promot. 2010;24(4):260–6. doi: 10.4278/ajhp.24.4.arb.
    1. Kalter-Leibovici O, Younis-Zeidan N, Atamna A, Lubin F, Alpert G, Chetrit A. et al.Lifestyle intervention in obese Arab women: a randomized controlled trial. Arch Intern Med. 2010;170(11):970–6. doi: 10.1001/archinternmed.2010.103.
    1. Sullivan S, Samuel S. Effect of short-term Pritikin diet therapy on the metabolic syndrome. J Cardiometab Syndr. 2006;Fall; 1(5):308–12.
    1. Albu JB, Heilbronn LK, Kelley DE, Smith SR, Azuma K, Berk ES, Pi-Sunyer FX, Ravussin E. Look AHEAD Adipose Research Group. Metabolic changes following a 1-year diet and exercise intervention in patients with type 2 diabetes. Diabetes. 2010;59(3):627–33. doi: 10.2337/db09-1239. Epub 2009 Dec 22.
    1. Hyman MA, Ornish D, Roizen M. Lifestyle medicine: treating the causes of disease. Altern Ther Health Med. 2009;15(6):12–4.
    1. National Cholesterol Education Program (NCEP) Expert Panel on Detection; Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–421.
    1. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health. Obes Res. 1998;6(Suppl 2):51S.
    1. American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2011;34:S62–S69.
    1. The IDF consensus worldwide definition of the metabolic syndrome. IDF. 2006.
    1. Harris MOR, Flomo D. Changing and Adhering to Lifestyle Change: What are the Keys? American Journal of Lifestyle Medicine. 2007;1(3):214–219. doi: 10.1177/1559827606298979.
    1. Serra-Majem L, Roman B, Estruch R. Scientific evidence of interventions using the Mediterranean diet: a systematic review. Nutr Rev. 2006;64(2 Pt 2):S27–47.
    1. de Kok TM, de Waard P, Wilms LC, van Breda SG. Antioxidative and antigenotoxic properties of vegetables and dietary phytochemicals: the value of genomics biomarkers in molecular epidemiology. Mol Nutr Food Res. 2010;54(2):208–17. doi: 10.1002/mnfr.200900288.
    1. Wing RR, Goldstein MG, Acton KJ, Birch LL, Jakicic JM, Sallis JF Jr. et al.Behavioral science research in diabetes: lifestyle changes related to obesity, eating behavior, and physical activity. Diabetes Care. 2001;24(1):117–23. doi: 10.2337/diacare.24.1.117.
    1. Murphy CT, McCarroll SA, Bargmann CI, Fraser A, Kamath RS, Ahringer J, Li H, Kenyon C. Genes that act downstream of DAF-16 to influence the lifespan of Caenorhabditis elegans. Nature. 2003;424(6946):277–83. doi: 10.1038/nature01789. Epub 2003 Jun 29.
    1. Lee SJ, Murphy CT, Kenyon C. Glucose shortens the life span of C. elegans by downregulating DAF-16/FOXO activity and aquaporin gene expression. Cell Metab. 2009;10(5):379–91. doi: 10.1016/j.cmet.2009.10.003.
    1. Buckland G, Bach A, Serra-Majem L. Obesity and the Mediterranean diet: a systematic review of observational and intervention studies. Obes Rev. 2008;9(6):582–93. doi: 10.1111/j.1467-789X.2008.00503.x. Epub 2008 Jun 10.
    1. U.S. Department of Health and Human Services. 2008 Physical Activity Guidelines for Americans. Hyattsville, MD: U.S. Department of Health and Human Services; 2008. Accessed July 26, 2010.
    1. Tresierras MA, Balady GJ. Resistance training in the treatment of diabetes and obesity: mechanisms and outcomes. J Cardiopulm Rehabil Prev. 2009;29(2):67–75.
    1. Roizen MF, Hafen T, Armour LA. The RealAge workout: maximum health, minimum work. 1. New York: Collins; 2006. p. xv. 216.
    1. Bravata DM, Smith-Spangler C, Sundaram V, Gienger AL, Lin N, Lewis R, Stave CD, Olkin I, Sirard JR. Using pedometers to increase physical activity and improve health: a systematic review. JAMA. 2007;298(19):2296–304. doi: 10.1001/jama.298.19.2296.
    1. Roizen MF, Oz M. You, on a diet: the owner's manual for waist management. Rev. and expanded. New York: Free Press; 2009.
    1. Nakao M, Fricchione G, Myers P, Zuttermeister PC, Baim M, Mandle CL, Medich C, Wells-Federman CL, Martin Arcari P, Ennis M, Barsky AJ, Benson H. Anxiety is a good indicator for somatic symptom reduction through behavioral medicine intervention in a mind/body medicine clinic. Psychother Psychosom. 2001;70(1):50–7. doi: 10.1159/000056225.
    1. Stevens J, Truesdale KP, McClain JE, Cai J. The definition of weight maintenance. Int J Obes (Lond) 2006;30(3):391–9. doi: 10.1038/sj.ijo.0803175.
    1. Frattaroli J, Weidner G, Dnistrian AM, Kemp C, Daubenmier JJ, Marlin RO, Crutchfield L, Yglecias L, Carroll PR, Ornish D. Clinical events in prostate cancer lifestyle trial: results from two years of follow-up. Urology. 2008;72(6):1319–23. doi: 10.1016/j.urology.2008.04.050.
    1. Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr. 1992;56(2):320–8.
    1. Nam BH, Kannel WB, D'Agostino RB. Search for an optimal atherogenic lipid risk profile: from the Framingham Study. Am J Cardiol. 2006;97(3):372–5. doi: 10.1016/j.amjcard.2005.08.055.
    1. Katcher HI, Hill AM, Lanford JL, Yoo JS, Kris-Etherton PM. Lifestyle approaches and dietary strategies to lower LDL-cholesterol and triglycerides and raise HDL-cholesterol. Endocrinol Metab Clin North Am. 2009;38(1):45–78. doi: 10.1016/j.ecl.2008.11.010.
    1. Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr. 1992;56(2):320–8.
    1. Poobalan A, Aucott L, Smith WC, Avenell A, Jung R, Broom J, Grant AM. Effects of weight loss in overweight/obese individuals and long-term lipid outcomes--a systematic review. Obes Rev. 2004;5(1):43–50. doi: 10.1111/j.1467-789X.2004.00127.x.
    1. Bayturan O, Tuzcu EM, Lavoie A, Hu T, Wolski K, Schoenhagen P, Kapadia S, Nissen SE, Nicholls SJ. The metabolic syndrome, its component risk factors, and progression of coronary atherosclerosis. Arch Intern Med. 2010;170(5):478–84. doi: 10.1001/archinternmed.2009.551.
    1. da Luz PL, Favarato D, Faria-Neto JR Jr, Lemos P, Chagas AC. High ratio of triglycerides to HDL-cholesterol predicts extensive coronary disease. Clinics (Sao Paulo) 2008;63(4):427–32.
    1. Ornish D. Avoiding revascularization with lifestyle changes: The Multicenter Lifestyle Demonstration Project. Am J Cardiol. 1998;82(10B):72T–76T.
    1. Nathan C, Ding A. Nonresolving inflammation. Cell. 2010;140(6):871–82. doi: 10.1016/j.cell.2010.02.029.
    1. Beavers KM, Nicklas BJ. Effects of lifestyle interventions on inflammatory markers in the metabolic syndrome. Front Biosci (Schol Ed) 2011;3:168–77. doi: 10.2741/s142.
    1. Lim S, Norman R, Clifton P, Noakes M. The effect of comprehensive lifestyle intervention or metformin on obesity in young women. Nutr Metab Cardiovasc Dis. 2011;21(4):261–8.
    1. Iqbal N, Vetter ML, Moore RH, Chittams JL, Dalton-Bakes CV, Dowd M, Williams-Smith C, Cardillo S, Wadden TA. Effects of a Low-intensity Intervention That Prescribed a Low-carbohydrate vs. a Low-fat Diet in Obese, Diabetic Participants. Obesity (Silver Spring) 2010;18(9):1733–8. doi: 10.1038/oby.2009.460.
    1. Murawski ME, Milsom VA, Ross KM, Rickel KA, DeBraganza N, Gibbons LM, Perri MG. Problem solving, treatment adherence, and weight-loss outcome among women participating in lifestyle treatment for obesity. Eat Behav. 2009;10(3):146–51. doi: 10.1016/j.eatbeh.2009.03.005.
    1. Fappa E, Yannakoulia M, Pitsavos C, Skoumas I, Valourdou S, Stefanadis C. Lifestyle intervention in the management of metabolic syndrome: could we improve adherence issues? Nutrition. 2008;24(3):286–91. doi: 10.1016/j.nut.2007.11.008. Epub 2008 Jan 16.
    1. Sullivan S, Cloninger CR, Przybeck TR, Klein S. Personality characteristics in obesity and relationship with successful weight loss. Int J Obes (Lond) 2007;31(4):669–74.

Source: PubMed

3
購読する